---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-286917"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2024-12-30T23:59:59+00:00"
generated_at: "2026-05-28T22:38:15.094680+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corcept submits NDA for relacorilant to treat Cushing's syndrome

## Summary
- NDA based on positive pivotal GRACE trial, Phase 3 GRADIENT, long-term extension and Phase 2 studies.
- No drug-induced adrenal insufficiency, hypokalemia, QT prolongation, or progesterone receptor effects seen.
- CEO Joseph Belanoff states relacorilant has potential to become standard of care for hypercortisolism.

## SEC filing metadata
- accession: 0001193125-24-286917
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2024-12-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000119312524286917/0001193125-24-286917-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000119312524286917/d834253d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-286917
- JSON: https://secwatch.observer/filing/0001193125-24-286917.json
- Plain text: https://secwatch.observer/filing/0001193125-24-286917.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.